Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.

Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. Variability may be due to active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this h...

Descripción completa

Detalles Bibliográficos
Autores principales: DiGiovanna, M. P., Carter, D., Flynn, S. D., Stern, D. F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074709/
https://www.ncbi.nlm.nih.gov/pubmed/8795585
_version_ 1782138024739471360
author DiGiovanna, M. P.
Carter, D.
Flynn, S. D.
Stern, D. F.
author_facet DiGiovanna, M. P.
Carter, D.
Flynn, S. D.
Stern, D. F.
author_sort DiGiovanna, M. P.
collection PubMed
description Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. Variability may be due to active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this hypothesis, we have developed an activation state-specific anti-HER-2/neu monoclonal antibody. In this report, we use this antibody to analyse the signalling status of HER-2/neu in a large series of invasive breast carcinomas. Overexpression of HER-2/neu was detected in 9% of 223 cases. Of the cases demonstrating overexpression, active signalling by HER-2/neu was detected in only 35%. The clinicopathological characteristics of these cases are described. This functional assay is predicted to improve the utility of HER-2/ neu as a prognostic indicator. IMAGES:
format Text
id pubmed-2074709
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20747092009-09-10 Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. DiGiovanna, M. P. Carter, D. Flynn, S. D. Stern, D. F. Br J Cancer Research Article Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. Variability may be due to active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this hypothesis, we have developed an activation state-specific anti-HER-2/neu monoclonal antibody. In this report, we use this antibody to analyse the signalling status of HER-2/neu in a large series of invasive breast carcinomas. Overexpression of HER-2/neu was detected in 9% of 223 cases. Of the cases demonstrating overexpression, active signalling by HER-2/neu was detected in only 35%. The clinicopathological characteristics of these cases are described. This functional assay is predicted to improve the utility of HER-2/ neu as a prognostic indicator. IMAGES: Nature Publishing Group 1996-09 /pmc/articles/PMC2074709/ /pubmed/8795585 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
DiGiovanna, M. P.
Carter, D.
Flynn, S. D.
Stern, D. F.
Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
title Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
title_full Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
title_fullStr Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
title_full_unstemmed Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
title_short Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
title_sort functional assay for her-2/neu demonstrates active signalling in a minority of her-2/neu-overexpressing invasive human breast tumours.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074709/
https://www.ncbi.nlm.nih.gov/pubmed/8795585
work_keys_str_mv AT digiovannamp functionalassayforher2neudemonstratesactivesignallinginaminorityofher2neuoverexpressinginvasivehumanbreasttumours
AT carterd functionalassayforher2neudemonstratesactivesignallinginaminorityofher2neuoverexpressinginvasivehumanbreasttumours
AT flynnsd functionalassayforher2neudemonstratesactivesignallinginaminorityofher2neuoverexpressinginvasivehumanbreasttumours
AT sterndf functionalassayforher2neudemonstratesactivesignallinginaminorityofher2neuoverexpressinginvasivehumanbreasttumours

Ejemplares similares